Relay Therapeutics, Inc.
RLAY- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001812364
In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 13 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Relay Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 161 | 172 | +11 |
| Shares | 130.2M | 130.5M | +275.2K (+0.2%) |
| Value | $1.64B | $1.10B | −$541.4M (−33.0%) |
New holders (23)
Institutions that held Relay Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (12)
Institutions that held Relay Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Artal Group S.A. | 1,213,725 | $15.2M |
| HighVista Strategies LLC | 32,197 | $404.4K |
| NinePointTwo Capital | 22,907 | $287.0K |
| Delphia (USA) Inc. | 16,848 | $211.6K |
| Qube Research & Technologies Ltd | 16,777 | $210.7K |
| US Bancorp | 129 | $1.62K |
| Red Tortoise LLC | 126 | $1.58K |
| Versant Capital Management, Inc | 90 | $1.13K |
| Signaturefd, LLC | 75 | $942 |
| Baker Avenue Asset Management, LP | 17 | $214 |
| AdvisorNet Financial, Inc | 3 | $38 |
| Disciplined Investments, LLC | 3 | $38 |